Design and synthesis of novel bispecific molecules for inducing BRD4 protein degradation

Abstract

Proteolysis targeting chimeras(PROTACs) are bispecific molecules containing a target protein binder and an ubiquitin ligase binder connected by a linker. Recently, some heterobifunctional small molecule bromodomain-containing protein 4(BRD4) degraders based on the concept of PROTACs were designed to induce the degradation of BRD4 protein. Herein, we synthesized a new class of PROTAC BRD4 degraders. One of the most promising compound 22f exhibited robust potency of BRD4 inhibition with IC₅₀ value of (9.4±0.6) nmol/L. Furthermore, compound 22f potently inhibited cell proliferation in BRD4-sensitive cell lines RS4;11 with IC₅₀ value of (27.6±1.6) nmol/L and capable of inducing degradation of BRD4 protein at 0.5―1.0 μmol/L in the RS4;11 cells. These data establish that compound 22f is a potent and efficacious BRD4 degrader.

Keywords

Proteolysis targeting chimera(PROTAC) / Bromodomain-containing protein 4(BRD4) degrader / Bromodomain-containing protein 4(BRD4) inhibitor

References

[1] Shi J., Vakoc C. R. Molecular cell, 2014, 54(5): 728.

[2] Belkina A. C., Denis G. V. Nature Reviews Cancer, 2012, 12(7): 465.

[3] Dawson M. A., Kouzarides T., Huntly B. J. P. N. Engl. J. Med., 2012, 367(7): 647.

[4] Arrowsmith C. H., Bountra C., Fish P. V., Lee K., Schapira M. Nat. Rev. Drug Discovery, 2012, 11(5): 384.

[5] Chung C. W. Prog. Med. Chem., 2012, 51: 1.

[6] Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W. B., Fedorov O., Morse E. M., Keates T., Hickman T. T., Felletar I., Philpott M., Munro S., McKeown M. R., Wang Y., Christie A. L., West N., Ca-meron M. J., Schwartz B., Heightman T. D., La Thangue N., French C. A., Wiest O., Kung A. L., Knapp S., Bradner J. E. Nature, 2010, 468(7327): 1067.

[7] Boi M., Gaudio E., Bonetti P., Kwee I., Bernasconi E., Tarantelli C., Rinaldi A., Testoni M., Cascione L., Ponzoni M., Mensah A. A., Sta-this A., Stussi G., Riveiro M. E., Herait P., Inghirami G., Cvitkovic E., Zucca E., Bertoni F. Clin. Cancer Res., 2015, 21(7): 1628.

[8] Sakamoto K. M., Kim K. B., Kumagai A., Mercurio F., Crews C. M., Deshaies R. J. Proc. Natl. Acad. Sci. USA, 2001, 98(15): 8554.

[9] Toure M., Crews C. M. Angew. Chem. Int. Ed., 2016, 55(6): 1966.

[10] Bondeson D. P., Mares A., Smith I. E. D., Ko E., Campos S., Miah A. H., Mulholland K. E., Routly N., Buckley D. L., Gustafson J. L., Zinn N., Grandi P., Shimamura S., Bergamini G., FaelthSavitski M., Bantscheff M., Cox C., Gordon D. A., Willard R. R., Flanagan J. J., Casillas L. N., Votta B. J., den Besten W., Famm K., Kruidenier L., Carter P. S., Harling J. D., Churcher I., Crews C. M. Nat. Chem. Biol., 2015, 11(8): 611.

[11] Winter G. E., Buckley D. L., Paulk J., Roberts J. M., Souza A., Dhe-Paganon S., Bradner J. E. Science, 2015, 348(6241): 1376.

[12] Lu J., Qian Y., Altieri M., Dong H., Wang J., Raina K., Hines J., Winkler J. D., Crew A. P., Coleman K., Crews C. M. Chem. Biol., 2015, 22(6): 755.

[13] Chen L., Yap J. L., Yoshioka M., Lanning M. E., Fountain R. N., Raje M., Scheenstra J. A., Strovel J. W., Fletcher S. ACS Med. Chem. Lett., 2015, 6(7): 764.

[14] Zhao L., Cao D., Chen T., Wang Y., Miao Z., Xu Y., Chen W., Wang X., Li Y., Du Z., Xiong B., Li J., Xu C., Zhang N., He J., Shen J. J. Med. Chem., 2013, 56(10): 3833.

[15] Lohbeck J., Miller A. K. Bioorg. Med. Chem. Lett., 2016, 26(21): 5260.